Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02135874 | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | completed | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 |
| clinicaltrials |
| NCT02081378 | A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | completed | Phase 1 | 326 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 18, 2024 | clinicaltrials |
| NCT04767802 | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit(PACIFIC) | completed | Phase 2 | 20 | Protagonist Therapeutics, Inc.INDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04384848 | The EMPATHY Pilot Study | completed | N/A | 94 | Northwestern UniversityOTHER | 2 | Mar 4, 2024 | clinicaltrials |
| NCT00235560 | Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients(LAM-RAPA) | completed | Phase 2 | 50 | University Hospital, ToulouseOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT02013648 | Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | completed | Phase 3 | 204 | University of UlmOTHER | 2 | Feb 23, 2024 | clinicaltrials |
| NCT03564288 | Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 14 | Oscotec Inc.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02222272 | Effect of 2nd Gen TKI in CML | completed | — | 432 | European Society for Blood and Marrow TransplantationNETWORK | 9 | Feb 20, 2024 | clinicaltrials |
| NCT06267898 | Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML | completed | — | 222 | European Society for Blood and Marrow TransplantationNETWORK | 3 | Feb 20, 2024 | clinicaltrials |
| NCT01812252 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant(ICT-HCT) | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03996096 | Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.(KIWIS) | completed | — | 50 | University Hospital, CaenOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT04169022 | AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells(CAR-LAM) | completed | N/A | 86 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT02057185 | Occupational Status and Hematological Disease(EMATO0113) | completed | — | 141 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03672695 | Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia. | completed | Phase 1 | 37 | Institut de Recherches Internationales ServierOTHER | 3 | Feb 5, 2024 | clinicaltrials |
| NCT02473146 | Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4(ALFA1401) | completed | Phase 2 / Phase 3 | 225 | Versailles HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT01041508 | Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia. | completed | Phase 1 | 18 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT01497002 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a(AML2004) | completed | Phase 3 | 1,222 | University of LeipzigOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01904136 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT02367456 | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients(BRIGHT 1012) | completed | Phase 1 | 73 | PfizerINDUSTRY | 6 | Jan 19, 2024 | clinicaltrials |
| NCT02461537 | Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML(ETAL3-ASAP) | completed | Phase 3 | 281 | DKMS gemeinnützige GmbHOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT06211452 | Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia | completed | Phase 3 | 258 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT03833180 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | completed | Phase 1 | 91 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT01394640 | Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients | completed | — | 124 | Paolo CorradiniOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02789254 | FLYSYN in MRD Positive AML(FLYSYN-101) | completed | Phase 1 / Phase 2 | 31 | Synimmune GmbHINDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT04439006 | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | completed | Phase 1 | 10 | Jennifer WoyachOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02626338 | Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | completed | Phase 1 / Phase 2 | 16 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT02400255 | Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients | completed | Phase 2 | 30 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | completed | Phase 1 | 282 | Deciphera Pharmaceuticals, LLCINDUSTRY | 6 | Dec 13, 2023 | clinicaltrials |
| NCT03734601 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT01288378 | Empirical Versus Preemptive Antifungal Therapy | completed | Phase 3 | 556 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Dec 11, 2023 | clinicaltrials |
| NCT05444972 | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review(METER) | completed | — | 998 | AbbVieINDUSTRY | 14 | Dec 11, 2023 | clinicaltrials |
| NCT06159816 | PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIES | completed | — | 300 | AUSL Romagna RiminiOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT02509546 | 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT00697684 | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant | completed | Phase 1 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT06148493 | Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database | completed | — | 425 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03455517 | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia(VeRitAs) | completed | Phase 2 | 77 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02543879 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 94 | Forma Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03961919 | Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant(FLAT-Auto) | completed | Phase 2 | 15 | Ciceri FabioOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03298984 | Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | completed | Phase 1 | 32 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00167219 | Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | completed | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02639559 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 22, 2024source: clinicaltrials